Global Cancer/Tumor Profiling Market Overview
The global cancer/tumor profiling market is witnessing substantial growth, primarily driven by the accelerating adoption of precision medicine and the rising global burden of cancer. Valued at USD 12.47 billion in 2024, the market is anticipated to reach USD 26.29 billion by 2033, expanding at a CAGR of 8.21% during 2025-2033. Growth is propelled by advancements in genomics and proteomics, the integration of personalized therapy models, and the growing use of biomarker-based diagnostic techniques.

In 2024, North America held over 42.8% of the total market share, supported by advanced healthcare systems, early adoption of oncology diagnostics, and strong investments in research and development.

Study Assumption Years

  • Base Year: 2024
  • Historical Years: 2019-2024
  • Forecast Years: 2025-2033

Cancer/Tumor Profiling Market Key Takeaways

  • Market Size and Growth: Valued at USD 12.47 billion in 2024 and projected to reach USD 26.29 billion by 2033, reflecting a CAGR of 8.21%.
  • Regional Leadership: North America led the market with a 42.8% share in 2024, driven by technological progress and strong diagnostic infrastructure.
  • Leading Cancer Type: Breast cancer remains the most prominent segment due to its high incidence rate and adoption of precision-based treatment approaches.
  • Technological Edge: Next-Generation Sequencing (NGS) remains pivotal for delivering deep genomic insights essential for biomarker detection.
  • Technique Focus: Genomics dominated with a 39.8% share in 2024, highlighting its significance in understanding genetic mutations and cancer mechanisms.
  • Application Scope: Personalized medicine continues to gain traction as it enables patient-specific therapeutic strategies.
  • Emerging Markets: Asia Pacific is exhibiting rapid growth due to rising cancer cases and increasing adoption of advanced diagnostic methods.

Request for a sample copy of this report: https://www.imarcgroup.com/cancer-tumor-profiling-market/requestsample

Market Growth Factors

Technological Advancements in Genomic and Proteomic Profiling
Continuous improvements in genomic and proteomic profiling are revolutionizing cancer diagnostics. Techniques such as NGS enable precise mutation identification and biomarker discovery, improving clinical decision-making and supporting the expansion of personalized therapies. Their integration into oncology practices underscores their growing role in modern cancer care.

Rising Cancer Incidence and Personalized Treatment Demand
With 20 million new cancer cases reported in 2022 and projections reaching 35 million by 2050, the need for effective and individualized treatment solutions is rising rapidly. Tumor profiling allows clinicians to tailor therapy based on a patient’s genetic makeup, enhancing treatment success and improving survival outcomes.

Government and Institutional Support for Oncology Research
Governments and private entities worldwide are significantly increasing investments in oncology research. For instance, the UK Government plans to boost R&D spending to 2.4% of GDP by 2027. Such initiatives are accelerating innovation in cancer diagnostics and promoting the integration of tumor profiling technologies in clinical settings.

Market Segmentation

By Cancer Type:

  • Breast Cancer – Largest segment due to high incidence and growing preference for customized therapies.
  • Lung Cancer – Increasing demand for early detection and targeted drug development.
  • Colorectal Cancer – Expanding adoption of molecular diagnostics and personalized medicine.
  • Prostate Cancer – Enhanced profiling techniques improving treatment precision.
  • Melanoma Cancer – Rising use of genetic profiling for designing targeted therapies.
  • Others – Includes additional cancers where profiling is gaining clinical relevance.

By Technology:

  • Next-Generation Sequencing (NGS)
  • Polymerase Chain Reaction (PCR)
  • Immunohistochemistry (IHC)
  • In-Situ Hybridization (ISH)
  • Microarray
  • Others

By Technique:

  • Genomics – Represented 39.8% of market share in 2024, leading the category.
  • Proteomics
  • Epigenetics
  • Metabolomics

By Application:

  • Personalized Medicine
  • Diagnostics
  • Biomarker Discovery
  • Prognostics
  • Others

Breakup by Region

  • North America (United States, Canada)
  • Asia Pacific (China, Japan, India, South Korea, Australia, Indonesia, Others)
  • Europe (Germany, France, United Kingdom, Italy, Spain, Russia, Others)
  • Latin America (Brazil, Mexico, Others)
  • Middle East and Africa

Regional Insights
North America continued to dominate the cancer/tumor profiling market in 2024, accounting for more than 42.8% of global revenue. This leadership is attributed to the region’s advanced healthcare ecosystem, wide availability of genomic diagnostics, and strong R&D funding. The adoption of biomarker testing and precision medicine is increasing, supported by favorable government initiatives and the presence of leading biotechnology firms.

Recent Developments & News

  • October 2024: Illumina partnered with AstraZeneca to co-develop NGS-based companion diagnostics for targeted cancer therapy.
  • September 2024: Thermo Fisher launched the Oncomine Comprehensive Assay Plus to improve mutation detection in solid tumors.
  • November 2023: Illumina released an enhanced version of TruSight Oncology 500 ctDNA v2, enabling deeper genomic analysis via liquid biopsy.
  • May 2023: Pfizer and Thermo Fisher Scientific collaborated to expand NGS-based testing access for breast and lung cancer patients across more than 30 countries.

Key Players

  • Abbott Laboratories
  • Becton Dickinson and Company
  • Caris Life Sciences
  • Exact Sciences Corporation
  • F. Hoffmann-La Roche Ltd
  • Hologic Inc.
  • HTG Molecular Diagnostics Inc.
  • Illumina Inc.
  • Laboratory Corporation of America Holdings
  • NeoGenomics Laboratories
  • Qiagen N.V.
  • Siemens AG
  • Sysmex Corporation

If you require any specific information that is not covered currently within the scope of the report, we will provide the same as a part of the customization.


Ask Analyst for Customization: https://www.imarcgroup.com/request?type=report&id=5231&flag=C

About Us
IMARC Group is a global management consulting firm that helps the world’s most ambitious changemakers to create a lasting impact. The company provides a comprehensive suite of market entry and expansion services. IMARC offerings include thorough market assessment, feasibility studies, company incorporation assistance, factory setup support, regulatory approvals and licensing navigation, branding, marketing and sales strategies, competitive landscape and benchmarking analyses, pricing and cost research, and procurement research.

Contact Us:
IMARC Group
134 N 4th St. Brooklyn, NY 11249, USA
Email: sales@imarcgroup.com
Tel No:(D) +91 120 433 0800
United States: +1-201-971-6302